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ABSTRACT 
The development of multitarget compounds against multifactorial diseases, such as 
Alzheimer’s disease, is an area of very intensive research, due to the expected superior 
therapeutic efficacy that should arise from the simultaneous modulation of several key 
targets of the complex pathological network. Here we describe the synthesis and 
multitarget biological profiling of a new class of compounds designed by molecular 
hybridization of an NMDA receptor antagonist fluorobenzohomoadamantanamine with 
the potent acetylcholinesterase (AChE) inhibitor 6-chlorotacrine, using two different 
linker lengths and linkage positions, to preserve or not the memantine-like polycyclic 
unsubstituted primary amine. The best hybrids exhibit greater potencies than parent 
compounds against AChE (IC50 0.33 nM in the best case, 44-fold increased potency 
over 6-chlorotacrine), butyrylcholinesterase (IC50 21 nM in the best case, 24-fold 
increased potency over 6-chlorotacrine), and NMDA receptors (IC50 0.89 µM in the best 
case, 2-fold increased potency over the parent benzohomoadamantanamine and 
memantine), which suggests an additive effect of both pharmacophoric moieties in the 
interaction with the primary targets. Moreover, most of these compounds have been 
predicted to be brain permeable. This set of biological properties makes them promising 
leads for further anti-Alzheimer drug development. 
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1. Introduction 
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that causes cognitive 
impairment and inexorably leads to dementia and death. With age being the main risk 
factor, the societal burden of AD in an increasingly aging population is reaching 
alarming proportions worldwide. The most worrisome predictions about AD prevalence, 
mortality, and associated economic costs are being continuously exceeded [1], thereby 
putting health systems and national economies at unmanageable risk if current drug 
discovery efforts do not result in efficacious treatments.  
Only four drugs are currently used for AD treatment, namely the acetylcholinesterase 
(AChE) inhibitors donepezil, galantamine, and rivastigmine, and the glutamate NMDA 
receptor antagonist memantine. These drugs address the marked impairment in 
neurotransmitter systems, prominently the cholinergic and the glutamatergic system that 
occur in AD patients as a consequence of synaptic dysfunction and neuronal death, 
which is one of the main histopathological hallmarks of AD. Other two common 
features are senile plaques and neurofibrillary tangles, which result from overproduction 
and aggregation of β-amyloid peptide (Aβ) and hyperphosphorylation and aggregation 
of tau protein, respectively. Despite some evidence of disease-modifying effects by the 
currently approved anti-Alzheimer drugs [2-7], they are regarded and used as 
symptomatic drugs. Since the launching of these drugs, research efforts have pursued 
the development of alternative neurotransmitter-based symptomatic therapies and, 
mainly, new drugs that act specifically on a given biological target or event with a 
prominent pathogenic role, in most cases related to Aβ and tau biology. Unfortunately, 
the enormous amounts of research efforts and resources that have been invested in the 
past three decades have not been corresponded by the discovery of novel drugs that 
have proven capable of halting or even just slowing down the neurodegenerative 
processes occurring in this fatal disease. Indeed, AD is one of the therapeutic areas with 
the highest attrition rates in clinical trials [8,9]. Very disappointingly, no drug candidate 
has successfully passed phase III clinical trials for AD since the launching of 
memantine, almost two decades ago. 
The repetitive failures of very promising target-specific drugs in clinical trials is leading 
to a growing awareness of the complex multifactorial nature of AD, which could result 
from the dysregulation of multiple separate but integrated signaling pathways. A 
scenario of a complex pathogenic network would account for the lack of efficacy of 
drugs that address a particular signaling pathway by modulation of a single biological 
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target, and warrants the development of alternative therapeutic approaches based on the 
simultaneous modulation of several crucial biological targets, which should result in 
additive or synergistic effects [10,11]. Multitarget treatments may involve the use of 
several specific drugs (drug cocktails or fixed-dose combinations) or a single drug with 
the ability to hit several biological targets (multitarget drugs). Even though the design 
and development of multitarget drugs can be very challenging [12], it has some clear 
advantages over multiple-medication therapies, such as simpler dose regimens and 
improved patient compliance, simpler pharmacokinetics and lack of drug‒drug 
interactions, and simpler clinical development, among others [13,14]. In fact, both 
strategies are being currently used in AD treatment or pursued in AD drug discovery. 
On the one hand, the combination of the AChE inhibitor donepezil with the glutamate 
NMDA antagonist memantine has proven to lead to additive or synergistic effects in 
mouse models and AD patients [15‒17], and a fixed-dose combination of both drugs 
(Namzaric®) is now being used as the standard of care to treat dementia associated with 
moderate to severe stages of the disease [18,19]. On the other hand, AD is one of the 
therapeutic areas where the development of multitarget drugs has been more intensively 
pursued in the past decade [20‒22]. Most of these compounds are hybrids that combine 
distinct pharmacophoric moieties to confer multiple activities [for recent examples see 
23‒37]. A crucial point in the design of multitarget anti-Alzheimer compounds is the 
selection of the biological targets to hit, and, hence, of the pharmacophores to be used. 
Many different combinations of targets have been considered, with most of them 
including AChE. Particularly, the mechanism of action of the currently marketed anti-
Alzheimer drugs and the fact that the combination of both mechanisms in the fixed-dose 
combination of an AChE inhibitor (donepezil) and a glutamate NMDA receptor 
antagonist (memantine) results in improved clinical efficacy have provided a valuable 
clue for the design of hybrid compounds that combine pharmacophoric moieties to 
impart those activities [38‒40]. Some of these compounds feature a moiety of a well-
known AChE inhibitor, such as galantamine or 7-methoxytacrine [41], linked through 
an oligomethylene tether to a memantine or the closely related amantadine unit 
(compounds 3-5, Figure 1) [42‒45]. These compounds exhibit nanomolar to 
submicromolar AChE inhibitory activities and low micromolar affinities towards 
glutamate NMDA receptors, slightly lower than that of memantine. Very interestingly, 
one of them, ARN14140, gave cognition enhancing effects and balanced the levels of 
biomarkers of neurodegeneration, synaptic plasticity, and apoptosis in a non-transgenic 
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mouse model of AD [43], thereby highlighting the therapeutic potential of the 
combination of AChE inhibition and NMDA receptor antagonism in a single multitarget 
molecule. 
 
Fig. 1. Structures of memantine, amantadine, and derivatives 3-5 with dual glutamate 
NMDA receptor affinity and AChE inhibitory activity. 
 
During the past decade we have been exploring the glutamate NMDA receptor 
antagonistic activity of novel polycyclic amines featuring oxaadamantane [46], 
noradamantane and bisnoradamantane [47], benzohomooxaadamantane [48], and 
benzohomoadamantane [49,50] scaffolds, as bioisosteric, ring-contracted or ring-
expanded analogs of memantine. Among these compounds, the 
fluorobenzohomoadamantanamine 6 (Figure 2) and its non-fluorinated analog turned 
out to be the most potent NMDA receptor antagonists, with potencies very close to that 
of memantine in a functional assay in rat cultured cerebellar granule neurons (CGN) 
[50]. 
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Fig. 2. Structure of the benzohomoadamantanamine 6 and design of the novel hybrids 
derived from 6 and the AChE inhibitor 6-chlorotacrine. 
 
The proven therapeutic potential of the combination of glutamate NMDA receptor 
antagonism with AChE inhibition, the interesting NMDA antagonistic activity of the 
benzohomoadamantanamine 6, and our own experience in the development of 
multitarget anti-Alzheimer compounds containing AChE inhibitor pharmacophores [51–
54] prompted us to undertake the design of a novel class of multitarget hybrid 
compounds featuring the aminopolycyclic scaffold of 6 and a unit of the potent AChE 
inhibitor 6-chlorotacrine [55] (Figure 2). In all memantine- or amantadine-based 
multitarget hybrids previously reported, the aminopolycyclic moiety is linked to the 
AChE inhibitor moiety through the amino group. It has been reported that alkylation 
(monomethylation) of the amino group of memantine leads to a twofold decrease of 
affinity and antagonistic activity towards NMDA receptors, whereas dialkylation has a 
much more dramatic effect (3-fold reduced affinity and 12-fold reduced NMDA 
antagonistic activity) [56]. This trend was also observed in some of the polycyclic 
amines we had developed as NMDA receptor antagonists [47,49,50], but not in all of 
them [46,48]. To further shed light on this, we envisaged the synthesis of two short 
series of benzohomoadamantane–chlorotacrine hybrids, where the attachment point of 
the aminopolycyclic moiety to the rest of the molecule was either the bridgehead 
aliphatic primary amino group or a second amino group placed at the benzene ring, 
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thereby leaving unsubstituted the “memantine-like” aliphatic amino group (Figure 2). A 
linker length similar to that used in the previously reported memantine- or amantadine-
based multitarget compounds was envisaged for the novel benzohomoadamantane–
chlorotacrine hybrids. 
Here we report the synthesis of this novel class of benzohomoadamantane–chlorotacrine 
hybrids and their in vitro biological profiling, including the determination of their 
inhibitory activity against both human cholinesterases (human AChE (hAChE) and 
human butyrylcholinesterase (hBChE)), glutamate NMDA receptor antagonistic 
activity, and brain permeability. Because other families of 6-chlorotacrine-related 
hybrids developed in our group have shown activity against the enzyme BACE-1 (β-
secretase) and Aβ42 and tau aggregation [51–54], the novel benzohomoadamantane–
chlorotacrine hybrids were also evaluated against these other targets of interest in AD 
treatment. 
 
2. Results and discussion 
2.1. Synthesis of the novel benzohomoadamantane–chlorotacrine hybrids 
The synthesis of the target hybrids 13a and 13b, in which the 
benzohomoadamantanamine moiety was linked throught its primary amino group to the 
chlorotacrine unit, was carried out by the alternative sequences depicted in Scheme 1, 
using 6-chlorotacrine, 7 [55], or the dichloroacridine derivative 8 [57] as the starting 
materials. We initially envisaged a four-step route that involved alkylation of 6-
chlorotacrine with the appropriate ω-bromoalkanenitrile, followed by hydrolysis of the 
cyano group, amide coupling of the resulting carboxylic acid with the 
benzohomoadamantanamine 6, and final reduction of the amide to the secondary amine. 
Reaction of 6-chlorotacrine, 7, with 5-bromovaleronitrile, in the presence of KOH in 
dry DMSO led in moderate yield (64%) to the new nitrile 11b, after silica gel column 
chromatography purification. However, different attempts to alkylate 7 with 4-
bromobutyronitrile failed to afford the shorter homologue 11a. The new nitrile 11a was 
alternatively obtained, in 92% overall yield, by amination of the dichloroacridine 
derivative 8 with 3-amino-1-propanol at 135 ºC, followed by mesylation of the resulting 
alcohol 9a [58], and reaction of mesylate 10a [58] with NaCN in dry DMF (Scheme 1). 
Alkaline hydrolysis of nitriles 11a and 11b, followed by acidification with an Et2O 
solution of HCl afforded the corresponding carboxylic acids, in the form of quinoline 
hydrochloride salts, which were directly coupled with amine 6 using EDC and HOBt, to 
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yield amides 12a and 12b in moderate yields (40% and 75% overall), after silica gel 
column chromatography purification. Reduction of amides 12a and 12b to the 
corresponding secondary amines turned out to be a difficult task. Different attempts of 
reduction with LiAlH4, LiBH4, or sodium bis(2-methoxyethoxy)aluminium hydride 
(Red-Al®) were fruitless. Finally, borane reduction of amides 12a and 12b did afford 
the target amines 13a and 13b, albeit in low yield (24% and 10%, respectively). 
Alternatively, amine 13b was obtained by alkylation of amine 6 with mesylate 10b, 
which was prepared by amination of chloroquinoline 8 with 5-amino-1-pentanol at 135 
ºC, followed by mesylation of the resulting alcohol 9b. Under these conditions, 13b was 
obtained in higher yield (27%) but it was accompanied with some byproducts arising 
from degradation of the mesylate. 
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Scheme 1. Reagents and conditions: (i) 7, KOH, DMSO, rt, 2 h; then, 5-
bromovaleronitrile, rt, overnight, 11b (64%); (ii)  3-amino-1-propanol or 5-amino-1-
pentanol, 135 ºC, 1 day, 9a (94%), 9b (40%); (iii) MsCl, Et3N, CH2Cl2, ‒10 ºC, 30 min, 
10a (quantitative), 10b (quantitative); (iv) NaCN, DMF, 100 ºC, 1 h, 11a (98%); (v) 1) 
40% methanolic KOH, MeOH, reflux, 3 h; then, water, reflux, overnight; HCl / Et2O; 2) 
crude carboxylic acid (quinoline hydrochloride salt), EDCꞏHCl, HOBt, Et3N, EtOAc / 
DMF, rt, 15 min; then, 6, EtOAc / DMF, rt, 2 days, 12a (40% overall yield from 11a), 
12b (75% overall yield from 11b); (vi) 6, K2CO3, DMF, 80 ºC, 2 days, 13b (27%); (vii) 
BH3ꞏTHF, THF, 0 ºC; then, rt, overnight, 13a (24%), 13b (10%). 
 
 
The synthesis of the second set of benzohomoadamantane–chlorotacrine hybrids, 18a 
and 18b, where the chlorotacrine unit and tether chain were attached to the benzene ring 
of the aminopolycyclic moiety, was carried out using benzohomoadamantanamine 14, 
previously prepared in our group [59], and nitriles 11a and 11b as the key building 
blocks (Scheme 2). Amine 14 was N-Boc-protected and then subjected to hydrogenation 
at atmospheric pressure and room temperature, in the presence of PtO2 as catalyst, to 
afford the aniline 16 in good yield. Amide coupling of 16 with the carboxylic acids 
derived from hydrolysis of nitriles 11a and 11b led to the N-Boc-protected hybrids 17a 
and 17b, which, upon treatment with 4N HCl / dioxane, were converted into the target 
hybrids 18a and 18b in moderate yield (49% and 37% overall yield from 11a and 11b, 
respectively). 
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Scheme 2. Reagents and conditions: (i) 2N NaOH, di-tert-butyl dicarbonate, rt, 16 h, 
87%; (ii) H2, PtO2, EtOH, 1 atm, rt, 4 h, 92%; (iii) 1) 40% methanolic KOH, MeOH, 
reflux, 3 h; then, water, reflux, overnight; HCl / Et2O; 2) crude carboxylic acid 
(quinoline hydrochloride salt), EDCꞏHCl, HOBt, Et3N, EtOAc / DMF, rt, 15 min; then, 
16, EtOAc / DMF, rt, 1 day; (iv)  4N HCl / dioxane, rt, 18 h, 18a (49% overall yield 
from 11a), 18b (37% overall yield from 11b). 
 
All the benzohomoadamantane–chlorotacrine hybrids were converted into the 
corresponding hydrochloride or dihydrochloride salts by treatment with HCl / MeOH, 
prior to their chemical characterization and biological profiling. 
 
 2.2. Acetylcholinesterase and butyrylcholinesterase inhibition by the novel 
benzohomoadamantane–chlorotacrine hybrids 
Apart from AChE, the enzyme BChE is in part responsible for the hydrolysis of the 
neurotransmitter acetylcholine (ACh) in the central nervous system (CNS), thereby 
contributing to the cholinergic deficit characteristic of AD patients. This is especially 
true in advanced stages of the disease, in which the levels of AChE are markedly 
decreased, whereas the levels of BChE remain the same or even increase, thereby 
acquiring a prominent role in ACh breakdown [60]. Thus, BChE inhibition or even 
more interestingly, dual AChE and BChE inhibition are commonly pursued in the 
search for novel anti-Alzheimer drug candidates. In this light, the effect of the novel 
benzohomoadamantane–chlorotacrine hybrids 12a,b, 13a,b, and 18a,b on human 
recombinant AChE (hAChE) and human serum BChE (hBChE) was determined by the 
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method of Ellman et al. [61]. 6-Chlorotacrine, 7, was also evaluated under the same 
assay conditions as a reference compound for cholinesterases inhibition (Table 1).  
 
Table 1 
Inhibitory activities against AChE and BChE, NMDA antagonistic activity, Aβ42 and 
tau anti-aggregating activity, and blood‒brain barrier (BBB) predicted permeabilities of 
the benzohomoadamantane‒chlorotacrine hybrids and reference compounds. 
Compd hAChE 
IC50 (nM)a 
hBChE  
IC50 (µM)a 
NMDA 
IC50 (µM)b 
Aβ42 
aggregation 
in E. coli 
(% inhib. 
at 10 μM)c 
Tau protein 
aggregation 
in E. coli  
(% inhib. 
at 10 μM)c 
Pe (10–6 cm s–1)d
(Prediction) 
12a 1.4 ± 0.1 2.3 ± 0.1 7.0 ± 2.8 < 5 10.2 ± 2.4 9.8 ± 0.9 (CNS+)
12b 1.3 ± 0.1 2.4 ± 0.2 8.3 ± 3.3 9.0 ± 1.2 12.6 ± 2.7 9.0 ± 0.5 (CNS+)
13a 2.0 ± 0.1 1.1 ± 0.1 3.3 ± 0.6 8.4 ± 2.2 22.0 ± 2.7 6.3 ± 0.1 (CNS+)
13b 1.4 ± 0.1 0.2 ± 0.0 0.9 ± 0.1 12.3 ± 2.6 20.7 ± 2.4 6.5 ± 0.3 (CNS+)
18a 0.3 ± 0.0 0.5 ± 0.0 1.2 ± 0.2 < 5 6.9 ± 3.9 2.7 ± 0.6 (CNS±)
18b 2.5 ± 0.5 0.02 ± 0.00 3.4 ± 1.2 < 5 22.9 ± 5.0 3.1 ± 0.7 (CNS±)
1 nde nde 1.5 ± 0.1 nde nde nde 
6 nde nde 1.9 ± 0.2 nde nde nde 
7 14.5 ± 0.9 0.5 ± 0.0 nde < 5 < 5 20 ± 0.4 (CNS+)
a IC50 inhibitory concentration (nM) towards human recombinant AChE and human 
serum BChE. IC50 values are expressed as mean ± standard error of the mean (SEM) of 
at least two experiments, each performed in triplicate. 
b Functional data were obtained from primary cultures of rat CGN challenged with 
NMDA (100 μM, in the presence of 10 μM glycine), by measuring the intracellular 
calcium concentration. Data shown are expressed as mean ± SEM of at least three 
separate experiments carried out on three different batches of cultured cells. 
c % Inhibition of Aβ42 and tau protein aggregation at 10 μM in intact E. coli cells. 
Values are expressed as mean ± SEM of four independent experiments (n = 4). 
d Permeability values from the PAMPA-BBB assay. Values are expressed as the mean ± 
SD of three independent experiments (n = 3). 
e Not determined. 
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All the novel hybrids turned out to be highly potent hAChE inhibitors, with IC50 values 
from subnanomolar (18a: 0.33 nM) to 2.5 nM (Table 1). Thus, the 
benzohomoadamantane–chlorotacrine hybrids are clearly more potent hAChE inhibitors 
(6–44-fold more potent) than the parent 6-chlorotacrine, 7, which is indicative of an 
additive or synergistic effect by the benzohomoadamantane moiety and/or the linker. In 
the first series, with IC50 values in the very narrow range of 1.30–1.96 nM, neither the 
linker length nor the presence of an amide or an amine as the attachment functionality to 
the benzohomoadamantane core seems to play a differential role in hAChE inhibition. 
Thus, amines 13a,b and amides 12a,b, longer and shorter homologues 12a-13a and 
12b-13b exhibited the same hAChE inhibitory potency. In contrast, in the second series, 
the shorter homologue 18a was 8-fold more potent than the longer homologue 18b. 
Indeed, 18a is the most potent hAChE inhibitor among all the novel 
benzohomoadamantane–chlorotacrine hybrids, so that the presence of an unsubstituted 
primary amino group at the benzohomoadamantane core and/or the presence of an 
amido linkage at the benzene ring with that particular linker length seem the most 
favorable substitution pattern for hAChE inhibition. 
In contrast to hAChE inhibition, a broader range of IC50 values for hBChE inhibition 
was found for the novel hybrids, i.e. from 21 nM (18b) to 2.36 µM (12b), as well as 
more defined structure–activity relationships. The presence of basic amino group at the 
benzohomoadamantane core seems to be important for hBChE inhibition, with 
secondary amines 13 being 2–11-fold more potent than their amido counterparts 12, and 
with the primary amines 18, with a different disposition of the linker, being still more 
potent (2–10-fold more potent than amines 13 and 5–100-fold more potent than amides 
12). Within the amines 13 and 18, a longer tether chain leads to a 5–23-fold greater 
hBChE inhibitory activity. Thus, the most potent hBChE inhibitors were hybrids 13b 
and 18b, which, with IC50 values of 210 and 21 nM, respectively, are 2- and 24-fold 
more potent than the parent 6-chlorotacrine. This supports the idea that the presence of 
the benzohomoadamantanamine moiety in these hybrids contributes positively to the 
interaction with the enzyme BChE. 
 
2.3. NMDA receptor antagonistic activity of the novel benzohomoadamantane–
chlorotacrine hybrids 
Apart from hAChE and hBChE, the NMDA receptor was the other primary biological 
target, which was pursued with the design of the benzohomoadamantane–chlorotacrine 
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hybrids. In particular, we inferred that the incorporation of the aminopolycyclic scaffold 
of the fluorobenzohomoadamantanamine 6, an NMDA receptor antagonist developed in 
our group [50] that is equipotent to memantine, into the structure of the hybrids should 
confer this additional activity. 
To assess the NMDA antagonistic activity of the novel hybrids, we performed a 
functional assay based on measuring their effects on the increase in intracellular calcium 
evoked by NMDA (100 µM, in the presence of 10 µM glycine) in cultured rat CGN 
loaded with Fura-2 [49]. Memantine, 1, and fluorobenzohomoadamantanamine 6 were 
used as reference compounds for NMDA antagonism (Table 1). 
As previously mentioned, in all the described memantine‒ or amantadine‒AChE 
inhibitor hybrids, the aminopolycyclic moiety is linked to the AChE inhibitor 
pharmacophore through its amino group. It has been described that alkylation of the 
amino group of memantine is detrimental for NMDA affinity and antagonistic activity, 
with monomethylation leading to a twofold reduced affinity and antagonistic activity, 
and dialkylation producing a 3-fold and 12-fold reduction of NMDA affinity and 
antagonistic activity, respectively [56]. A similar trend was also observed in some 
polycyclic amines that were developed in our group as NMDA receptor antagonists 
[47,49,50], whereas the opposite trend was found in others [46,48]. In line with our 
previous reports, alkylation of the bridgehead amino group of the 
benzohomoadamantane core in the novel hybrids may lead to reduced (13a vs 6, 
twofold reduction) or increased (13b vs 6, twofold increase) NMDA antagonistic 
activity, with the linker length seeming to play a role (the longer homologue 13b is 4-
fold more potent than the shorter counterpart 13a). Indeed, the most potent NMDA 
antagonist among the hybrids that are substituted at the bridgehead amino group, 13b, is 
equipotent to the most potent hybrid featuring an unsubstituted bridgehead primary 
amino group, 18a. Thus, it seems that this class of compounds can tolerate 
monoalkylation of the polycyclic amino group without losing NMDA antagonistic 
activity. However, acylation of this amino group seems to be clearly detrimental for 
NMDA antagonistic activity, with amides 12a and 12b being 2- and 9-fold less potent 
than amines 13a and 13b. These results are in agreement with those found in 
memantine‒galantamine hybrids, where amido-linked hybrids displayed NMDA 
affinities 2‒4-fold lower than those of the corresponding amines [42]. Therefore, the 
presence of a basic nitrogen atom at a bridgehead position of the polycyclic core seems 
to be favourable for NMDA antagonistic activity. 
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Overall, hybrids 13b and 18a are roughly twofold more potent NMDA antagonists than 
the parent benzohomoadamantanamine 6, which may be indicative of an additive effect 
of the chlorotacrine moiety in the interaction of the hybrids with these receptors. 
Moreover, these novel hybrids are equipotent or slightly more potent (1.7-fold) than the 
NMDA antagonistic anti-Alzheimer drug memantine. 
 
2.4. Evaluation of potential anti-amyloid activities of the novel benzohomoadamantane–
chlorotacrine hybrids 
It has been shown that memantine inhibits in vitro the aggregation of human 
recombinant Aβ42 in a concentration-dependent manner, through NMDA receptor-
independent mechanisms [62]. Also, chronic treatment with memantine leads to reduced 
brain levels of insoluble Aβ and soluble Aβ oligomers in several animal models of AD. 
On the other hand, we have found that some classes of oligomethylene-linked 6-
chlorotacrine-based hybrids can inhibit in a cell-based assay the aggregation of the two 
amyloidogenic proteins involved in AD pathogenesis, i.e. Aβ and tau [52]. Additionally, 
other families of hybrid compounds featuring a huprine moiety, closely related to 6-
chlorotacrine, as AChE inhibitor pharmacophore, have been shown to inhibit in vitro 
BACE-1, the enzyme that catalyzes the first and rate-limiting step of Aβ production 
from the amyloid precursor protein (APP) [53,63,64], with IC50 values ranging from 
nanomolar to low micromolar. 
In the light of these findings, the presence in the novel hybrids of a 6-chlorotacrine unit 
and a benzohomoadamantanamine moiety, structurally related to memantine, prompted 
us to screen them for their potential inhibitory activity on Aβ and tau aggregation and 
BACE-1. 
To assess the Aβ and tau anti-aggregating activity of the hybrids, we used a cell-based 
assay in intact Escherichia coli cells that overexpress either Aβ42, the most 
aggregation-prone and neurotoxic form of Aβ, or tau, which upon expression form 
insoluble inclusion bodies that can be stained with thioflavin S [65,66]. When tested at 
an inhibitor concentration of 10 µM, low percentages of inhibition were found both for 
Aβ42 (up to 12%) and for tau (up to 23%) (Table 1), so these compounds are weak anti-
aggregating compounds. We had found very similar results in other tacrine- and 6-
chlorotacrine-based hybrids that feature a cycloaliphatic ring as the second 
pharmacophoric moiety [51], whereas much better anti-aggregating activities were 
found for 6-chlorotacrine- and huprine-based hybrids bearing as the second 
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pharmacophore a polycyclic heteroaromatic system [52,53,67]. Thus, the presence of an 
extended aromatic system, apart from that of 6-chlorotacrine or huprine, seems to be a 
favourable structural requirement in this class of hybrid compounds for a good anti-
aggregating activity of Aβ42, tau, and other amyloidogenic protein involved in other 
major human disorders [67]. 
Finally, we assessed the in vitro inhibitory activity of the novel hybrids towards human 
recombinant BACE-1, to find that they are essentially inactive or very weak inhibitors, 
with percentages of inhibition up to 18% at 5 µM. Even though the presence of a 
chlorotacrine unit, which should be mostly protonated in the acidic endosomal 
compartments where BACE-1 localizes, should enable a favourable salt bridge 
interaction with the aspartate residues of the catalytic dyad, the weak inhibitory activity 
of these hybrids should result from unfavourable secondary interactions of the 
benzohomoadamantane moiety within the large binding site of BACE-1.   
 
2.5. Brain permeation 
CNS drugs must be able to efficiently enter into the brain by crossing the blood‒brain 
barrier (BBB). Hybrid compounds resulting from the pharmacophore combination 
approach tend to have rather large molecular weights, which might compromise their 
ability to cross biological membranes, including BBB [68,69].  
However, an increasing number of structurally diverse anti-Alzheimer hybrid 
compounds with molecular weights over 500 have shown good brain permeability in in 
vivo studies in mice [22]. As a preliminary assessment of brain permeability, the novel 
benzohomoadamantane–chlorotacrine hybrids were subjected to the parallel artificial 
membrane permeation assay-BBB (PAMPA-BBB), a well-established in vitro model of 
passive transcellular permeation [70]. In this method, the permeability (Pe) of the target 
compounds through a lipid extract of porcine brain is determined using a 70:30 mixture 
of phosphate-buffered saline (PBS)/EtOH. The assay was validated by correlating the 
experimental and reported Pe values of 14 known drugs (Section 4.2.5, Experimental 
Part). From the resulting linear correlation [Pe (exp) = 1.5758 Pe (lit) – 1.1459 (R2 = 
0.9241)] and the limits established by Di et al. for BBB permeation [70], a threshold of 
Pe (106 cm s1) > 5.2  was set for compounds with high BBB permeation (CNS+), and 
thresholds of Pe (106 cm s1) < 2.0 and 5.2 > Pe (106 cm s1) > 2.0 were established for 
low (CNS–) and uncertain (CNS±) BBB permeation, respectively. For the two hybrids 
that feature an unsubstituted bridgehead amino group, i.e. 18a and 18b, an uncertain 
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BBB permeation was predicted, whereas all the benzohomoadamantane–chlorotacrine 
hybrids of the first series, i.e. substituted at the bridgehead amino group, were predicted 
to be able to cross the BBB (Table 1), which anticipates their ability to enter the brain 
and reach their different CNS targets. 
 
3. Conclusion 
Molecular hybridization of the NMDA antagonist fluorobenzohomoadamantanamine 6 
with the potent AChE inhibitor 6-chlorotacrine, 7, using a 4- and 5-carbon-atom tether 
chain attached at the bridgehead amino group or at an additional amino group on the 
benzene ring of the benzohomoadamantane core, has led to a new class of multitarget 
compounds that share the activities of the parent compounds on their primary targets. 
The effect of the different linkage position is apparent in hBChE inhibition, where 
hybrids that feature a memantine-like unsubstituted amino group are significantly more 
potent that those with the linker attached at that amino group. However, for hAChE 
inhibition and NMDA antagonism, the linkage position does not have a clear effect, 
with the potencies depending on tether length and/or the presence of a basic bridgehead 
nitrogen atom. The novel hybrids are particularly potent on hAChE (IC50 in the 
0.33‒1.96 nM range) and then on hBChE (IC50 in the 0.021‒2.36 µM range) and 
NMDA receptors (IC50 in the 0.89‒8.29 µM range), but they seem to be devoid of 
activity on proteins other than their primary biological targets, showing weak inhibitory 
activity on Aβ42 and tau aggregation and BACE-1. 
The increased potencies of all or some of the new hybrids relative to the parent 
compounds from which they were designed suggests that both pharmacophoric moieties 
are positively contributing to the interactions with all the primary targets. Indeed, all 
hybrids are clearly more potent hAChE inhibitors (up to 44-fold) than the parent 6-
chlorotacrine (IC50 14.5 nM), and some of them are also more potent for hBChE 
inhibition (up to 24-fold) than 6-chlorotacrine (IC50 0.50 µM) and up to 2-fold more 
potent NMDA antagonists than the parent fluorobenzohomoadamantanamine 6 (IC50 
1.93 µM) and memantine (IC50 1.50 µM). Overall, the most interesting 
benzohomoadamantane‒chlorotacrine hybrids, 13b, 18a, and 18b compare well with 
previously reported memantine‒ and amantadine‒AChE inhibitor hybrids such as 3-5 
(Figure 1), in terms of AChE inhibition and NMDA antagonism, and take on added 
value a nanomolar or submicromolar hBChE inhibitory activity, thereby constituting 
interesting leads for future multitarget anti-Alzheimer drug discovery programs. 
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4. Experimental part 
4.1. Chemistry. General methods.  
All reagents were obtained from commercial suppliers (Sigma Aldrich, Acros, Cymit) 
unless otherwise stated, and used without further purification. The reactions were 
monitored by thin-layer chromatography (TLC) using aluminium-backed sheets with 
silica gel 60 F254 (Merck, ref 1.05554). The spots were visualized by UV irradiation and 
/ or 1% aq. KMnO4, followed by charring with a heat-gun. Column chromatography 
was performed on silica gel 60 AC.C (35−70 mesh, SDS, ref 2000027). Melting points 
were determined in open capillary tubes with a MFB 595010M Gallenkamp melting 
point apparatus. IR spectra were run on a Perkin Elmer Spectrum RX I 
spectrophotometer. Absorption values are expressed as wavenumbers (cm-1); only 
significant absorption bands are given. 400 MHz 1H/ 100.6 MHz 13C NMR spectra were 
recorded on a Varian Mercury 400 spectrometer, at the Centres Científics i Tecnologics 
of the University of Barcelona (CCiTUB). The chemical shifts are reported in ppm (δ 
scale) relative to solvent signals (CD3OD at 3.31 and 49.0 ppm in the 1H and 13C NMR 
spectra, respectively; CDCl3 at 7.26 and 77.00 ppm in the 1H and 13 C NMR spectra, 
respectively), and coupling constants are reported in Hertz (Hz). Assignments given for 
the NMR spectra of the new compounds have been carried out by comparison with the 
NMR data of compounds 12b, 13b, and 18b, which in turn, were assigned on the basis 
of COSY 1H/1H (standard procedures) and COSY 1H/13C (gHSQC and gHMBC 
sequences) experiments. High resolution mass spectra were carried out at the CCiTUB 
with a LC/MSD TOF Agilent Technologies spectrometer. 
 
4.1.1. 5-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-1-pentanol (9b) 
A mixture of 6,9-dichloro-1,2,3,4-tetrahydroacridine, 8 (1.50 g, 5.95 mmol) and 5-
amino-1-pentanol (7.76 mL, 7.36 g, 71.3 mmol) was stirred at 135 ºC for 1 day. The 
mixture was cooled to room temperature, poured onto water (200 mL), diluted with 5N 
NaOH (50 mL), and extracted with EtOAc (3  100 mL). The combined organic 
extracts were dried over anhydrous Na2SO4 and evaporated at reduced pressure, to give 
a dark brown oily residue (2.50 g), which was purified through column chromatography 
(35–70 μm silica gel, CH2Cl2 /MeOH / 50% aq. NH4OH mixtures, gradient elution). On 
elution with CH2Cl2 /MeOH / 50% aq. NH4OH 97:3:0.4, alcohol 9b (767 mg, 40% 
yield) was isolated as a yellow solid; Rf 0.32 (CH2Cl2 / MeOH / 50% aq. NH4OH 
95:5:1). 
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A solution of 9b (55 mg, 0.17 mmol) in CH2Cl2 (1 mL) was filtered through a 0.2 μm 
PTFE filter, treated with a methanolic solution of HCl (0.5 M, 1.0 mL), and evaporated 
at reduced pressure. The solid was washed with pentane (3  2 mL) to give, after drying 
at 65 ºC / 2 Torr for 48 h, 9bꞏHCl (61 mg) as a beige solid: mp 148–150 °C; IR (ATR) ν 
3400–2400 (max at 3250, 2924, 2859, O–H, N–H, +N–H, C–H st), 1629, 1567, 1513 
(Ar–C–C, Ar–C–N st) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.51 (m, 2H, 3-H2), 1.67 
(m, 2H, 2-H2), 1.88 (m, 2H, 4-H2), 1.92–2.20 (m, 4H, 2’-H2, 3’-H2), 2.68 (t, J = 6.0 Hz, 
2H, 1’-H2), 3.00 (t, J = 6.0 Hz, 2H, 4’-H2), 3.57 (t, J = 6.4 Hz, 2H, 1-H2), 3.96 (t, J = 
7.2 Hz, 2H, 5-H2), 4.85 (s, +NH, NH, OH), 7.57 (dd, J = 9.2 Hz, J’ = 2.0 Hz, 1H, 7’-H), 
7.77 (d, J = 2.0 Hz, 1H, 5’-H), 8.40 (d, J = 9.2 Hz, 1H, 8’-H); 13C NMR (100.6 MHz, 
CD3OD) δ 21.8 (CH2, C3’), 22.9 (CH2, C2’), 24.1 (CH2, C3), 24.7 (CH2, C1’), 29.3 
(CH2, C4’), 31.1 (CH2, C4), 33.0 (CH2, C2), 48.8 (CH2, C5), 62.6 (CH2, C1), 113.4 (C, 
C9a’), 115.4 (C, C8a’), 119.1 (CH, C5’), 126.8 (CH, C7’), 128.8 (CH, C8’), 140.1 (C, 
C6’), 140.5 (C, C10a’), 152.1 (C, C4a’), 157.9 (C, C9’); HRMS (ESI), calcd for 
[C18H2335ClN2O + H+] 319.1578, found 319.1585. 
 
4.1.2. 5-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]pentyl methanesulfonate 
(10b) 
A solution of alcohol 9b (368 mg, 1.15 mmol) and anhydrous Et3N (0.27 mL, 197 mg, 
1.95 mmol) in dry CH2Cl2 (7 mL) was cooled at –10 ºC with an ice / NaCl bath, and, 
then, treated dropwise with methanesulfonyl chloride (0.13 mL, 192 mg, 1.68 mmol). 
The reaction mixture was stirred at –10 ºC for 30 min and concentrated in vacuo. The 
residue was taken up in CH2Cl2 (20 mL), washed with 2N NaOH (3 × 15 mL), dried 
over anhydrous Na2SO4, and evaporated at reduced pressure, to afford mesylate 10b 
(461 mg, quantitative yield) as a dark brown oil; Rf 0.72 (CH2Cl2 / MeOH / 50% aq. 
NH4OH 95:5:1). 
A solution of 10b (25 mg, 0.06 mmol) in CH2Cl2 (1 mL) was filtered through a 
0.2 μm PTFE filter and evaporated in vacuo. The resulting solid was washed with 
pentane (3 × 2 mL), to afford, after drying at 65 ºC / 2 Torr for 48 h, the analytical 
sample of 10b (24 mg) as a dark brown oil; IR (ATR) ν 3286 (N–H st), 1634, 1604, 
1574, 1555 (Ar–C–C, Ar–C–N st) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.54 (m, 2H, 3-
H2), 1.70–1.84 (m, 4H, 2-H2, 4-H2), 1.86–1.93 (m, 4H, 2’-H2, 3’-H2), 2.67 (t, 2H, 1’-
H2), 2.99 (s, 3H, CH3SO3), 3.03 (m, 2H, 4’-H2), 3.58 (m, 2H, 5-H2), 4.24 (t, J = 6.4 Hz, 
2H, 1-H2), 7.25 (dd, J = 9.2 Hz, J’ = 2.0 Hz, 1H, 7’-H), 7.88 (d, J = 2.0 Hz, 1H, 5’-H), 
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7.93 (d, J = 9.2 Hz, 1H, 8’-H); 13C NMR (100.6 MHz, CDCl3, this compound 
decomposed partially during acquisition of the spectrum, only some representative 
signals are given) δ 22.1 (CH2), 22.7 (CH2), 22.8 (CH2) (C3, C2’, C3’), 24.7 (CH2, C1’), 
28.8 (CH2, C4), 30.9 (CH2, C2), 32.6 (CH2, C4’), 37.4 (CH3, OSO2CH3), 48.8 (CH2, 
C5), 69.5 (CH2, C1), 114.9 (C, C9a’), 117.5 (C, C8a’), 151.7 (C, C4a’), 157.9 (C, C9’); 
HRMS (ESI), calcd for [C19H2535ClN2O3 + H+] 397.1347, found 397.1353. 
 
4.1.3. 4-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]butanenitrile (11a) 
A mixture of mesylate 10a [58] (2.32 g, 5.58 mmol) and NaCN (1.64 g, 33.5 mmol) in 
dry DMF (5 mL) was stirred at 100 ºC for 1 h, neutralized with 1N NaOH (50 mL), and 
extracted with CH2Cl2 (4 × 30 mL). The combined organic extracts were washed with 
water (6 × 40 mL), dried over anhydrous Na2SO4, and evaporated under reduced 
pressure, to give nitrile 11a (1.61 g, 98% yield) as a brown oil; Rf 0.68 (CH2Cl2 / MeOH 
/ 50% aq. NH4OH 95:5:1). 
A solution of 11a (142 mg, 0.47 mmol) in CH2Cl2 (1 mL) was filtered through a 0.2 μm 
PTFE filter, treated with a methanolic solution of HCl (0.5 M, 0.8 mL), and evaporated 
at reduced pressure. The solid was washed with pentane (3  2 mL) to give, after drying 
at 65 ºC / 2 Torr for 48 h, 11aꞏHCl (154 mg) as a brown solid: mp 114–116 °C; IR 
(ATR) ν 3500–2500 (max at 3050, 2930, 2861, 2761, N–H, +N–H, C–H st), 2232 (CN 
st), 1629, 1567, 1514 (Ar–C–C, Ar–C–N st) cm–1; 1H NMR (400 MHz, CD3OD) δ 
1.92–2.02 (m, 4H, 2’-H2, 3’-H2), 2.18 (tt, J = J’ = 7.2 Hz, 2H, 3-H2), 2.62 (t, J = 7.2 Hz, 
2H, 2-H2), 2.73 (t, J = 6.0 Hz, 2H, 1’-H2), 3.02 (t, J = 5.6 Hz, 2H, 4’-H2), 4.08 (t, J = 
7.2 Hz, 2H, 4-H2), 4.85 (s, +NH, NH), 7.58 (dd, J = 9.2 Hz, J’ = 2.0 Hz, 1H, 7’-H), 7.80 
(d, J = 2.0 Hz, 1H, 5’-H), 8.39 (d, J = 9.2 Hz, 1H, 8’-H); 13C NMR (100.6 MHz, 
CD3OD) δ 15.1 (CH2, C2), 21.7 (CH2, C3’), 22.9 (CH2, C2’), 25.0 (CH2, C1’), 27.1 
(CH2, C3), 29.4 (CH2, C4’), 47.8 (CH2, C4), 113.9 (C, C9a’), 115.5 (C, C8a’), 119.2 
(CH, C5’), 120.5 (C, C1), 127.1 (CH, C7’), 128.6 (CH, C8’), 140.2 (C, C6’), 140.4 (C, 
C10a’), 152.6 (C, C4a’), 157.9 (C, C9’); HRMS (ESI), calcd for [C17H1835ClN3 + H+] 
300.1262, found 300.1265. 
 
4.1.4. 5-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]pentanenitrile (11b) 
A mixture of 6-chlorotacrine, 7 (1.50 g, 6.45 mmol), finely powdered KOH (85% 
purity, 851 mg, 12.9 mmol), and 4 Å molecular sieves in dry DMSO (20 mL) was 
stirred, heating every 10 min with a heat gun for 1 h, and at room temperature for 1 
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additional h, and it was then treated with 5-bromovaleronitrile (0.9 mL, 1.25 g, 7.71 
mmol). The reaction mixture was stirred at room temperature overnight, then diluted 
with 5N NaOH (350 mL), and extracted with EtOAc (3 × 150 mL). The combined 
organic extracts were washed with water (3 × 200 mL), dried over anhydrous Na2SO4, 
and evaporated under reduced pressure, to give a yellow oily residue (2.28 g), which 
was subjected to column chromatography purification (35−70 μm silica gel, CH2Cl2 / 
50% aq. NH4OH 100:0.4), to afford nitrile 11b (1.30 g, 64% yield) as a light yellow 
solid; Rf 0.73 (CH2Cl2 / MeOH / 50% aq. NH4OH 95:5:1). 
A solution of 11b (21 mg, 0.07 mmol) in CH2Cl2 (1 mL) was filtered through a 0.2 μm 
PTFE filter, treated with a methanolic solution of HCl (0.5 M, 0.4 mL), and evaporated 
at reduced pressure. The solid was washed with pentane (3  2 mL) to give, after drying 
at 65 ºC / 2 Torr for 48 h, 11bꞏHCl (35 mg) as a yellow solid: mp 73–75 °C; IR (ATR) ν 
3500–2500 (max at 3126, 3043, 2920, 2857, N–H, +N–H, C–H st), 2236 (CN st), 1631, 
1573, 1515 (Ar–C–C, Ar–C–N st) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.78 (m, 2H, 
3-H2), 1.92–2.02 (m, 6H, 4-H2, 2’-H2, 3’-H2), 2.54 (t, J = 6.0 Hz, 2H, 2-H2), 2.70 (t, 2H, 
1’-H2), 3.00 (t, 2H, 4’-H2), 4.00 (t, J = 7.2 Hz, 2H, 5-H2), 4.85 (s, +NH, NH), 7.57 (dd, J 
= 9.2 Hz, J’ = 2.0 Hz, 1H, 7’-H), 7.78 (d, J = 2.0 Hz, 1H, 5’-H), 8.39 (d, J = 9.2 Hz, 1H, 
8’-H); 13C NMR (100.6 MHz, CD3OD) δ 17.5 (CH2, C2), 21.9 (CH2, C3’), 23.0 (CH2, 
C2’), 24.1 (CH2, C3), 25.2 (CH2, C1’), 29.6 (CH2, C4’), 30.6 (CH2, C4), 49.9 (CH2, 
C5), 113.7 (C, C9a’), 115.6 (C, C8a’), 119.3 (CH, C5’), 120.9 (C, C1), 127.1 (CH, C7’), 
128.9 (CH, C8’), 140.1 (C, C6’), 140.5 (C, C10a’), 152.4 (C, C4a’), 157.9 (C, C9’); 
HRMS (ESI), calcd for [C18H2035ClN3 + H+] 314.1419, found 314.1416. 
 
4.1.5. 4-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-N-(9-fluoro-7H-
5,6,8,9,10,11-hexahydro-5,9:7,11-dimethanobenzo[9]annulen-7-yl)butanamide (12a) 
A solution of nitrile 11a (1.53 g, 5.20 mmol) in MeOH (6.5 mL) was treated with a 40% 
methanolic solution of KOH (13 mL). The resulting suspension was stirred under reflux 
for 3 h, then treated with water (21 mL), and again stirred under reflux overnight. The 
resulting solution was cooled to room temperature and evaporated in vacuo. The 
resulting residue was treated with HCl / Et2O (0.73 N, 142 mL), and the mixture was 
concentrated in vacuo to give the corresponding carboxylic acid in the form of 
hydrochloride salt (7.42 g), which was used in the following step without further 
purification. 
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To a suspension of crude carboxylic acid (1.94 g of a crude that could contain a 
maximum of 1.36 mmol of the carboxylic acid) in a mixture of EtOAc (25 mL) and 
DMF (2 mL), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC 
hydrochloride) (316 mg, 1.65 mmol), Et3N (0.94 mL, 685 mg, 6.78 mmol), and 1-
hydroxy-1H-benzotriazole (HOBt) (185 mg, 1.36 mmol) were added. The resulting 
mixture was stirred at room temperature for 15 min, and then treated with a suspension 
of amine 6 (346 mg, 1.50 mmol) in a mixture of EtOAc (16 mL) and DMF (2 mL). The 
reaction mixture was stirred at room temperature for 2 days, then concentrated in vacuo, 
diluted with 1N NaOH (200 mL), and extracted with CH2Cl2 (2 × 150 mL). The 
combined organic extracts were washed with water (5 × 100 mL), dried over anhydrous 
Na2SO4, and evaporated under reduced pressure to give a brown oil (696 mg), which 
was subjected to column chromatography purification (35−70 μm silica gel, CH2Cl2 / 
MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution with CH2Cl2 / MeOH / 
50% aq. NH4OH 99.8:0.2:0.4, amide 12a (288 mg, 40% yield) was isolated as a brown 
oil; Rf 0.53 (CH2Cl2 / MeOH / 50% aq. NH4OH 95:5:1). 
A solution of 12a (26 mg, 0.05 mmol) in CH2Cl2 (1 mL) was filtered through a 0.2 μm 
PTFE filter, treated with a methanolic solution of HCl (0.5 M, 0.3 mL), and evaporated 
at reduced pressure. The solid was washed with pentane (3  2 mL) to give, after drying 
at 65 ºC / 2 Torr for 48 h, 12aꞏHCl (27 mg) as a yellow solid: mp 169–173 ºC; IR 
(ATR) ν 3500–2400 (max at 3246, 3054, 2917, 2852, 2795, N–H, +N–H, C–H st), 1631, 
1584, 1574 (C=O, Ar–C–C, Ar–C–N st) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.80 [br 
d, J = 10.8 Hz, 2H, 10”(13”)-HA], 1.90–1.95 (m, 4H, 2’-H2, 3’-H2), 1.98–2.17 [m, 10H, 
3-H2, 6”(12”)-HA, 6”(12”)-HB, 10”(13”)-HB, 8”-H2], 2.37 (t, J = 6.4 Hz, 2H, 2-H2), 2.69 
(br signal, 2H, 1’-H2), 2.97 (br signal, 2H, 4’-H2), 3.21 [m, 2H, 5”(11”)-H], 3.97 (t, J = 
6.4 Hz, 2H, 4-H2), 4.86 (s, +NH, NH), 7.06–7.14 [m, 4H, 1”(4”)-H, 2”(3”)-H], 7.49 (dd, 
J = 9.2 Hz, J’ = 2.0 Hz, 1H, 7’-H), 7.75 (d, J = 2.0 Hz, 1H, 5’-H), 8.41 (d, J = 9.2 Hz, 
1H, 8’-H); 13C NMR (100.6 MHz, CD3OD) δ 21.8 (CH2, C3’), 22.8 (CH2, C2’), 25.0 
(CH2, C1’), 26.5 (CH2, C3), 29.3 (CH2, C4’), 34.8 (CH2, C2), 39.3 [CH2, d, JC-F = 1.3 
Hz, C6”(12”)], 40.9 [CH, d, JC-F = 12.9 Hz, C5”(11”)], 41.3 [CH2, d, JC-F = 20.0 Hz, 
C10”(13”)], 46.9 (CH2, d, JC-F = 18.1 Hz, C8”), 49.3 (CH2, C4), 58.8 (C, d, JC-F = 11.0 
Hz, C7”), 94.7 (C, d, JC-F = 176.8 Hz, C9”), 113.4 (C, C9a’), 115.4 (C, C8a’), 119.0 
(CH, C5’), 126.7 (CH, C7’), 128.0 [CH, C2”(3”)], 129.0 (CH, C8’), 129.1 [CH, 
C1”(4”)], 140.1 (C, C6’), 140.5 (C, C10a’), 146.2 [C, C4a”(11a”)], 151.9 (C, C4a’), 
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157.9 (C, C9’), 174.4 (C, C1); HRMS (ESI), calcd for [C32H3535ClFN3O + H+] 
532.2525, found 532.2525. 
 
 
 
4.1.6. 5-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-N-(9-fluoro-7H-
5,6,8,9,10,11-hexahydro-5,9:7,11-dimethanobenzo[9]annulen-7-yl)pentanamide (12b) 
This compound was prepared as described for 12a. From nitrile 11b (1.24 g, 4.04 
mmol), crude carboxylic acid (6.17 g) was obtained as the hydrochloride salt and used 
in the following step without further purification. From crude carboxylic acid (1.21 g of 
a crude that could contain a maximum of 0.79 mmol of carboxylic acid) and amine 6 
(200 mg, 0.87 mmol), a brown solid residue (1.87 g) was obtained and subjected to 
column chromatography purification (35−70 μm silica gel, CH2Cl2 / MeOH / 50% aq. 
NH4OH mixtures, gradient elution). On elution with CH2Cl2 / MeOH / 50% aq. NH4OH 
99:1:0.4 to 98.5:1.5:0.4, amide 12b (324 mg, 75% yield) was isolated as a yellow oil; Rf 
0.61 (CH2Cl2 / MeOH / 50% aq. NH4OH 95:5:1). 
A solution of 12b (36 mg, 0.07 mmol) in CH2Cl2 (1 mL) was filtered through a 0.2 μm 
PTFE filter, treated with a methanolic solution of HCl (0.5 M, 0.4 mL), and evaporated 
at reduced pressure. The solid was washed with pentane (3  2 mL) to give, after drying 
at 65 ºC / 2 Torr for 48 h, 12bꞏHCl (38 mg) as a yellow solid: mp 181–185 ºC; IR 
(ATR) ν 3500–2500 (max at 3193, 3126, 3043, 2915, 2857, N–H, +N–H, C–H st), 1632, 
1589, 1571 (C=O, Ar–C–C, Ar–C–N st) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.68 (m, 
2H, 3-H2), 1.77–1.85 [m, 4H, 4-H2,10”(13”)-HA], 1.91–1.95 (m, 4H, 2’-H2, 3’-H2), 
1.98–2.15 [m, 8H, 6”(12”)-HA, 6”(12”)-HB, 10”(13”)-HB, 8”-H2], 2.20 (t, J = 6.8 Hz, 
2H, 2-H2), 2.67 (br signal, 2H, 1’-H2), 2.98 (br signal, 2H, 4’-H2), 3.20 [m, 2H, 5”(11”)-
H], 3.94 (t, J = 6.8 Hz, 2H, 5-H2), 4.85 (s, +NH, NH), 7.06–7.13 [m, 4H, 1”(4”)-H, 
2”(3”)-H], 7.53 (dd, J = 9.2 Hz, J’ = 2.4 Hz, 1H, 7’-H), 7.76 (d, J = 2.4 Hz, 1H, 5’-H), 
8.39 (d, J = 9.2 Hz, 1H, 8’-H); 13C NMR (100.6 MHz, CD3OD) δ 21.7 (CH2, C3’), 22.8 
(CH2, C2’), 23.6 (CH2, C3), 24.8 (CH2, C1’), 29.3 (CH2, C4’), 30.5 (CH2, C4), 36.7 
(CH2, C2), 39.3 [CH2, d, JC-F = 2.0 Hz, C6”(12”)], 40.9 [CH, d, JC-F = 12.9 Hz, 
C5”(11”)], 41.3 [CH2, d, JC-F = 20.0 Hz, C10”(13”)], 46.8 (CH2, d, JC-F = 18.1 Hz, C8”), 
48.8 (CH2, C5), 58.7 (C, d, JC-F = 11.6 Hz, C7”), 94.7 (C, d, JC-F = 176.8 Hz, C9”), 
113.5 (C, C9a’), 115.5 (C, C8a’), 119.1 (CH, C5’), 126.8 (CH, C7’), 128.0 [CH, 
C2”(3”)], 128.8 (CH, C8’), 129.1 [CH, C1”(4”)], 140.1 (C, C6’), 140.5 (C, C10a’), 
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146.2 [C, C4a”(11a”)], 152.1 (C, C4a’), 157.8 (C, C9’), 174.8 (C, C1); HRMS (ESI), 
calcd for [C33H3735ClFN3O + H+] 546.2682, found 546.2685. 
 
4.1.7. N-(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)-N’-(9-fluoro-7H-5,6,8,9,10,11-
hexahydro-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-1,4-butanediamine (13a) 
A solution of amide 12a (124 mg, 0.22 mmol) in dry THF (5 mL) was cooled to 0 ºC 
with an ice bath, and then treated dropwise with BH3ꞏTHF (1M in THF, 0.87 mL, 0.87 
mmol). The reaction mixture was stirred at room temperature overnight. The resulting 
mixture was cooled to 0 ºC, and treated dropwise with MeOH (3 mL) and water (3 mL). 
The organic phase was evaporated under reduced pressure, and the aqueous phase was 
diluted with 1N NaOH (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The combined 
organic extracts were dried over anhydrous Na2SO4 and evaporated in vacuo, to give a 
beige solid residue (111 mg), which was subjected to column chromatography 
purification (35−70 μm silica gel, hexane / EtOAc / 50% aq. NH4OH mixtures, gradient 
elution). On elution with hexane / EtOAc / 50% aq. NH4OH 50:50:0.4, starting 12a (41 
mg) was recovered. On elution with hexane / EtOAc / 50% aq. NH4OH 40:60:0.4, 
amine 13a (27 mg, 24% yield) was isolated as a yellow sticky solid; Rf 0.45 (CH2Cl2 / 
MeOH / 50% aq. NH4OH 95:5:1). 
A solution of 13a (27 mg, 0.05 mmol) in CH2Cl2 (1 mL) was filtered through a 0.2 μm 
PTFE filter, treated with a methanolic solution of HCl (0.5 M, 0.3 mL), and evaporated 
at reduced pressure. The solid was washed with pentane (3  2 mL) and recrystallized 
from MeOH / EtOAc 1:1 (1 mL), to give, after drying at 65 ºC / 2 Torr for 48 h, the 
analytical sample of 13aꞏ2HCl (7 mg), as a pale yellow solid: 1H NMR (400 MHz, 
CD3OD) δ 1.81 (m, 2H, 2-H2), 1.86–2.03 (m, 10H, 3-H2, 2’-H2, 3’-H2, 6”(12”)-HA, 
10”(13”)-HA], 2.14–2.26 [m, 6H, 6”(12”)-HB, 10”(13”)-HB, 8”-H2], 2.71 (m, 2H, 1’-H2), 
3.00 (m, 2H, 4’-H2), 3.08 (t, J = 7.6 Hz, 2H, 1-H2), 3.41 [m, 2H, 5”(11”)-H], 4.01 (t, J = 
7.2 Hz, 2H, 4-H2), 4.85 (s, +NH, NH), 7.16 [m, 4H, 1”(4”)-H, 2”(3”)-H], 7.58 (dd, J = 
8.8 Hz, J’ = 2.0 Hz, 1H, 7’-H), 7.77 (d, J = 2.0 Hz, 1H, 5’-H), 8.41 (d, J = 8.8 Hz, 1H, 
8’-H); 13C NMR (100.6 MHz, CD3OD) δ 21.7 (CH2, C3’), 22.9 (CH2, C2’), 24.9 (CH2, 
C1’), 25.1 (CH2, C3), 28.5 (CH2, C2), 29.4 (CH2, C4’), 36.6 [CH2, C6”(12”)], 40.0 [CH, 
d, JC-F = 13.1 Hz, C5”(11”)], 40.7 [CH2, d, JC-F = 20.1 Hz, C10”(13”)], 41.2 (CH2, C1), 
44.4 (CH2, d, JC-F = 21.1 Hz, C8”), 49.7 (CH2, C4), 63.8 (C, d, JC-F = 11.1 Hz, C7”), 
94.2 (C, d, JC-F = 180.1 Hz, C9”), 113.8 (C, C9a’), 115.6 (C, C8a’), 119.2 (CH, C5’), 
127.0 (CH, C7’), 128.6 [CH, C2”(3”)], 128.7 (CH, C8’), 129.4 [CH, C1”(4”)], 140.1 (C, 
 24
C6’), 140.6 (C, C10a’), 145.1 [C, C4a”(11a”)], 152.5 (C, C4a’), 157.9 (C, C9’); HRMS 
(ESI), calcd for [C32H3735ClFN3 + H+] 518.2733, found 518.2710. 
 
4.1.8. N-(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)-N’-(9-fluoro-7H-5,6,8,9,10,11-
hexahydro-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-1,5-pentanediamine (13b) 
4.1.8.1. From 12b. This compound was prepared as decribed for 13a. From amide 12b 
(100 mg, 0.18 mmol), an orange solid residue (79 mg) was obtained and subjected to 
column chromatography purification (35−70 μm silica gel, hexane / EtOAc / Et3N 
mixtures, gradient elution). On elution with hexane / EtOAc / Et3N 30:70:0.2, amine 
13b (10 mg, 10% yield) was isolated as a yellow solid; Rf 0.45 (CH2Cl2 / MeOH / 50% 
aq. NH4OH 95:5:1). 
A solution of 13b (10 mg, 0.02 mmol) in CH2Cl2 (1 mL) was filtered through a 0.2 μm 
PTFE filter, treated with a methanolic solution of HCl (1.35 M, 0.13 mL), and 
evaporated at reduced pressure. The solid was washed with pentane (3  2 mL), to give, 
after drying at 65 ºC / 2 Torr for 48 h, the analytical sample of 13bꞏ2HCl (12 mg), as a 
yellow solid: 1H NMR (400 MHz, CD3OD) δ 1.55 (tt, J = J’ = 7.6 Hz, 2H, 3-H2), 1.77 
(tt, J = J’ = 7.6 Hz 2H, 2-H2), 1.85–1.99 [m, 10H, 4-H2, 2’-H2, 3’-H2, 6”(12”)-HA, 
10”(13”)-HA], 2.16–2.26 [m, 6H, 6”(12”)-HB, 10”(13”)-HB, 8”-H2], 2.70 (m, 2H, 1’-H2), 
3.00 (m, 2H, 4’-H2), 3.04 (t, J = 7.6 Hz, 2H, 1-H2), 3.41 [m, 2H, 5”(11”)-H], 3.97 (t, J = 
7.6 Hz, 2H, 5-H2), 4.85 (s, +NH, NH), 7.15 [m, 4H, 1”(4”)-H, 2”(3”)-H], 7.57 (dd, J = 
9.6 Hz, J’ = 2.0 Hz, 1H, 7’-H), 7.78 (d, J = 2.0 Hz, 1H, 5’-H), 8.41 (d, J = 9.6 Hz, 1H, 
8’-H); 13C NMR (100.6 MHz, CD3OD) δ 21.7 (CH2, C3’), 22.9 (CH2, C2’), 24.8 (2 
CH2, C1’, C3), 27.4 (CH2, C2), 29.3 (CH2, C4’), 30.8 (CH2, C4), 36.5 [CH2, C6”(12”)], 
40.0 [CH, d, JC-F = 13.0 Hz, C5”(11”)], 40.7 [CH2, d, JC-F = 20.6 Hz, C10”(13”)], 41.3 
(CH2, C1), 44.3 (CH2, d, JC-F = 20.7 Hz, C8”), 49.2 (CH2, C5), 63.7 (C, d, JC-F = 11.0 
Hz, C7”), 94.2 (C, d, JC-F = 180.0 Hz, C9”), 113.5 (C, C9a’), 115.5 (C, C8a’), 119.1 
(CH, C5’), 126.9 (CH, C7’), 128.5 [CH, C2”(3”)], 128.8 (CH, C8’), 129.4 [CH, 
C1”(4”)], 140.1 (C, C6’), 140.5 (C, C10a’), 145.2 [C, C4a”(11a”)], 152.2 (C, C4a’), 
157.9 (C, C9’); HRMS (ESI), calcd for [C33H3935ClFN3 + H+] 532.2889, found 
532.2906.  
4.1.8.2. From 10b. A solution of mesylate 10b (237 mg, 0.60 mmol) in DMF (1.5 mL) 
was added to a stirred suspension of amine 6 (115 mg, 0.42 mmol) and K2CO3 (130 mg, 
0.94 mmol) in DMF. The reaction mixture was stirred at 80 ºC for 2 days and then it 
was concentrated in vacuo. The resulting residue was taken up in water (15 mL) and 2N 
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NaOH (15 mL), and extracted with CH2Cl2 (3×20 mL). The combined organic extracts 
were dried over anhydrous Na2SO4 and evaporated at reduced pressure, to give a dark 
brown oil (309 mg), which was subjected to column chromatography purification 
(35−70 μm silica gel, CH2Cl2 / MeOH / 50% aq. NH4OH mixtures, gradient elution). On 
elution with CH2Cl2 / MeOH / 50% aq. NH4OH 98.6:1.4:0.4, byproduct 6-chloro-9-(5-
chloropentylamino)-1,2,3,4-tetrahydroacridine (38 mg) was isolated. On elution with 
CH2Cl2 / MeOH / 50% aq. NH4OH 97:3:0.4, an inseparable 1.5:1 mixture of the desired 
amide 13b and byproduct 5-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-1-pentanol 
(86 mg, 27% yield of 13b) was obtained. 
 
4.1.9. tert-Butyl (9-fluoro-7H-5,6,8,9,10,11-hexahydro-2-nitro-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)carbamate (15) 
To a mixture of amine 14 [59] (496 mg, 1.79 mmol) and 2N NaOH (1.4 mL) in THF 
(3.5 mL), di-tert-butyl dicarbonate (355 mg, 1.62 mmol) was added. The reaction 
mixture was stirred at room temperature for 16 h, then cooled in an ice bath, neutralized 
with 2N HCl, and extracted with EtOAc. The combined organic extracts were dried 
over anhydrous Na2SO4 and evaporated in vacuo, to give the N-Boc protected amine 15 
(589 mg, 87% yield): mp 204–205 ºC; IR (NaCl) ν 3426 (N–H st), 1725, 1714 (C=O st), 
1608, 1588, 1520, 1505 (NO2 st as), 1391, 1360, 1345, 1306, 1285 (NO2 st s) cm–1; 1H 
NMR (400 MHz, CDCl3) δ 1.41 [s, 9H, C(CH3)3], 1.88–2.24 (m, 10H, methylene 
protons), 3.37 (m, 2H, 5-H, 11-H), 4.58 (br.s., 1H, NHCOO), 7.25 (dd, J = 7.2 Hz, J’ = 
2.0 Hz, 1H, 3-H), 7.97–8.00 (m, 2H, 1-H, 4-H); 13C NMR (100.6 MHz, CDCl3) δ 28.5 
[CH3, C(CH3)3], 38.2 (CH2), 38.5 (CH2) (C6, C12), 39.51 (CH, d, JC-F = 13.3 Hz), 39.59 
(CH, d, JC-F = 13.3 Hz) (C5, C11), 39.55 (CH2, d, JC-F = 21.3 Hz), 39.8 (CH2, d, JC-F = 
20.7 Hz) (C10, C13), 46.1 (CH2, d, JC-F = 18.2 Hz, C8),  56.3 (C, d, JC-F = 11.3 Hz, C7), 
79.8 (C, C(CH3)3], 93.6 (C, d, JC-F = 178.5 Hz, C9),  122.3 (CH), 123.3 (CH) (C1, C4), 
129.4 (CH, C3), 146.3 (C), 146.9 (C) (C4a, C11a), 152.4 (C, C2), 154.1 (C, NHCOO); 
HRMS (ESI), calcd for [C20H25FN2O4 – H–] 375.1726, found 375.1738. 
 
4.1.10. tert-Butyl (2-amino-9-fluoro-7H-5,6,8,9,10,11-hexahydro-5,9:7,11-
dimethanobenzo[9]annulen-7-yl)carbamate (16) 
A suspension of the nitro derivative 15 (583 mg, 1.54 mmol) and PtO2 (48 mg, 0.12 
mmol) in EtOH (100 mL) was hydrogenated at 1 atm of H2 at room temperature for 4 h. 
The resulting black suspension was filtered and the filtrate was evaporated at reduced 
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pressure to give amine 16 (495 mg, 92 % yield) as a yellow solid: mp 118–120 ºC; IR 
(NaCl) ν 3411, 3363 (N–H st), 1713 (C=O st), 1616, 1586, 1505 (NO2 st as), 1453, 
1391, 1365, 1340, 1306, 1282 (NO2 st s) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.42 [s, 
9H, C(CH3)3], 1.83–2.20 (m, 10H, methylene protons), 3.06 (m, 1H), 3.11 (m, 1H) (5-
H, 11-H), 3.24 (br.s., 1H), 3.90 (br.s., 1H) (2-NH2), 4.51 (br.s., 1H, NHCOO), 6.427 
(dd, J = 6.4 Hz, J’ = 2.4 Hz, 1H, 3-H), 6.434 (d, J = 2.4 Hz, 1H, 1-H), 6.85 (d,  J = 6.4 
Hz, 1H, 4-H); 13C NMR (100.6 MHz, CDCl3) δ 28.6 [CH3, C(CH3)3], 38.7 (CH, d, JC-F 
= 13.3 Hz, C5), 38.9 (CH2), 39.6 (CH2) (C6, C12), 39.8 (CH, d, JC-F = 13.5 Hz, C11), 
40.2  (CH2, d, JC-F = 20.1 Hz), 40.7  (CH2, d, JC-F = 19.5 Hz) (C10, C13), 46.4  (CH2, d, 
JC-F = 17.1 Hz, C8), 56.6 (C, d, JC-F = 11.5 Hz, C7), 79.4 [C, C(CH3)3], 94.6 (C, d, JC-F 
= 177.0 Hz, C9),  113.1 (CH), 115.3 (CH (C1, C3), 129.3 (CH, C4), 135.2 (C, C2), 
145.1 (C), 145.9 (C) (C4a, C11a), 154.1 (C, NHCOO); HRMS (ESI), calcd for 
[C20H27FN2O2 + H+] 347.2129, found 347.2132. 
 
4.1.11. N-(7-Amino-9-fluoro-7H-5,6,8,9,10,11-hexahydro-5,9:7,11-
dimethanobenzo[9]annulen-2-yl)-4-[(6-chloro-1,2,3,4-tetrahydroacridin-9-
yl)amino]butanamide (18a) 
N-{7-[(tert-Butoxycarbonyl)amino]-9-fluoro-7H-5,6,8,9,10,11-hexahydro-5,9:7,11-
dimethanobenzo[9]annulen-2-yl}-4-[(6-chloro-1,2,3,4-tetrahydroacridin-9-
yl)amino]butanamide (17a) was prepared as described for 12a. From nitrile 11a (369 
mg, 1.23 mmol), crude carboxylic acid (2.55 g) was obtained as the hydrochloride salt 
and used in the following step without further purification. From this crude carboxylic 
acid and amine 16 (302 mg, 0.87 mmol), a brown sticky solid residue (3.11 g) was 
obtained and subjected to column chromatography purification (35−70 μm silica gel, 
hexane / EtOAc / Et3N mixtures, gradient elution). On elution with hexane / EtOAc / 
Et3N 20:80:0.2 to 10:90.5:0.2, impure amide 17a (235 mg) was isolated as a yellow oil 
and used in the following step without further purification; Rf 0.72 (CH2Cl2 / MeOH / 
50% aq. NH4OH 95:5:1); LRMS (ESI), 647.3159 (M + H+). 
A mixture of N-Boc-protected amide 17a (218 mg) and HCl / dioxane (4N solution, 2.4 
mL, 9.61 mmol) was stirred at room temperature for 18 h. The resulting mixture was 
evaporated under reduced pressure, to give a brown solid which was taken up in water 
(3 mL), alkalinized with 10% aq. Na2CO3 (15 mL), and extracted with a mixture MeOH 
/ CHCl3 1:9 (4 × 10 mL). The combined organic extracts were dried over anhydrous 
Na2SO4 and concentrated in vacuo, to give a light brown oily residue (213 mg), which 
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was subjected to column chromatography purification (35−70 μm silica gel, CH2Cl2 / 
MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution with CH2Cl2 / MeOH / 
50% aq. NH4OH 98.5:1.5:0.4 to 95:5:0.4, amine 18a (91 mg, 19% overall yield from 
amine 16) was isolated as a white solid; Rf 0.22 (CH2Cl2 / MeOH / 50% aq. NH4OH 
95:5:1). 
A solution of 18a (50 mg, 0.09 mmol) in CH2Cl2 (2 mL) was filtered through a 0.2 μm 
PTFE filter, treated with a methanolic solution of HCl (3N solution, 0.3 mL), and 
evaporated at reduced pressure. The solid was washed with pentane (3  2 mL), to give, 
after drying at 65 ºC / 2 Torr for 48 h, the analytical sample of 18aꞏ2HCl (49 mg), as a 
white solid: 1H NMR (400 MHz, CD3OD) δ 1.80–1.96 (m, 8H, 2’-H2, 3’-H2, 6”-HA, 
10”-HA, 12”-HA, 13”-HA), 2.06–2.26 (m, 8H, 3-H2, 6”-HB, 8”-H2, 10”-HB, 12”-HB, 13”-
HB), 2.58 (t, J = 6.4 Hz, 2H, 2-H2), 2.69 (t, J = 5.6 Hz, 2H, 1’-H2), 2.94 (t, J = 6.0 Hz, 
2H, 4’-H2), 3.32 (m, 1H, 11”-H), 3.38 (m, 1H, 5”-H), 4.07 (t, J = 6.8 Hz, 2H, 4-H2), 
4.85 (s, +NH, NH), 7.10 (d, J = 8.4 Hz, 1H, 4”-H), 7.27 (dd, J = 8.4 Hz, J’ = 2.4 Hz, 1H, 
3”-H), 7.36 (d, J = 2.4 Hz, 1H, 1”-H), 7.52 (dd, J = 9.2 Hz, J’ = 2.4 Hz, 1H, 7’-H), 7.76 
(d, J = 2.4 Hz, 1H, 5’-H), 8.46 (d, J = 9.2 Hz, 1H, 8’-H); 13C NMR (100.6 MHz, 
CD3OD) δ 21.7 (CH2, C3’), 22.8 (CH2, C2’), 24.8 (CH2, C1’), 26.5 (CH2, C3), 29.3 
(CH2, C4’), 35.1 (CH2, C2), 38.6 (CH2), 38.8 (CH2) (C6”, C12”), 39.5 (CH, d, JC-F = 
13.5 Hz, C5”), 40.4 (CH, d, JC-F = 12.9 Hz, C11”), 40.7(CH2, d, JC-F = 19.4 Hz, C10”, 
C13”), 45.9 (CH2, d, JC-F = 20.7 Hz, C8”), 49.1 (CH2, C4), 58.1 (C, d, JC-F = 10.3 Hz, 
C7”), 94.0 (C, d, JC-F = 179.3 Hz, C9”), 113.4 (C, C9a’), 115.4 (C, C8a’), 119.0 (CH, 
C5’), 119.6 (CH, C3”), 120.9 (CH, C1”), 126.7 (CH, C7’), 129.0 (CH, C8’), 130.0 (CH, 
C4”), 138.9 (C, C2”), 140.0 (C, C6’), 140.5 (C, C10a’), 141.0 (C, C4a”), 145.8 (C, 
C11a”), 151.9 (C, C4a’), 157.9 (C, C9’), 173.5 (C, C1); HRMS (ESI), calcd for 
[C32H3635ClFN4O + H+] 547.2634, found 547.2632. 
 
4.1.12. N-(7-Amino-9-fluoro-7H-5,6,8,9,10,11-hexahydro-5,9:7,11-
dimethanobenzo[9]annulen-2-yl)-5-[(6-chloro-1,2,3,4-tetrahydroacridin-9-
yl)amino]pentanamide (18b) 
This compound was prepared as described for 17a. From nitrile 11b (1.10 g, 3.51 
mmol), crude carboxylic acid (5.80 g) was obtained as the hydrochloride salt and used 
in the following step without further purification. From this crude carboxylic acid and 
amine 16 (575 mg, 1.66 mmol), a brown sticky solid residue (9.84 g) was obtained and 
subjected to column chromatography purification (35−70 μm silica gel, hexane / EtOAc 
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/ Et3N mixtures, gradient elution). On elution with hexane / EtOAc / Et3N 10:90:0.2 to 
0:100:0.2, impure N-{7-[(tert-butoxycarbonyl)amino]-9-fluoro-7H-5,6,8,9,10,11-
hexahydro-5,9:7,11-dimethanobenzo[9]annulen-2-yl}-5-[(6-chloro-1,2,3,4-
tetrahydroacridin-9-yl)amino]pentanamide (17b, 312 mg) was isolated as a brown oil 
and used in the following step without further purification; Rf 0.72 (CH2Cl2 / MeOH / 
50% aq. NH4OH 95:5:1); LRMS (ESI), 661.3323 (M + H+). 
From N-Boc-protected amide 17b (303 mg) and HCl / dioxane (4N solution, 3.3 mL, 
13.0 mmol), a light brown oily residue (261 mg) was obtained and subjected to column 
chromatography purification (35−70 μm silica gel, CH2Cl2 / MeOH / 50% aq. NH4OH 
mixtures, gradient elution). On elution with CH2Cl2 / MeOH / 50% aq. NH4OH 
98:2:0.4, amine 18b (94 mg, 10% overall yield from amine 16) was isolated as a white 
solid; Rf 0.45 (CH2Cl2 / MeOH / 50% aq. NH4OH 95:5:1). 
A solution of 18b (19 mg, 0.03 mmol) in CH2Cl2 (1 mL) was filtered through a 0.2 μm 
PTFE filter, treated with a methanolic solution of HCl (3N solution, 0.03 mL), and 
evaporated at reduced pressure. The solid was washed with pentane (3  2 mL), to give, 
after drying at 65 ºC / 2 Torr for 48 h, the analytical sample of 18bꞏ2HCl (22 mg), as a 
yellow solid: 1H NMR (400 MHz, CD3OD) δ 1.78–2.00 (m, 12H, 3-H2, 4-H2, 2’-H2, 3’-
H2, 6”-HA, 10”-HA, 12”-HA, 13”-HA), 2.06–2.19 (m, 6H, 6”-HB, 8”-H2, 10”-HB, 12”-HB, 
13”-HB), 2.45 (t, J = 7.2 Hz, 2H, 2-H2), 2.70 (t, J = 5.2 Hz, 2H, 1’-H2), 2.99 (t, J = 5.2 
Hz, 2H, 4’-H2), 3.29–3.34 (m, 1H, 11”-H), 3.38 (m, 1H, 5”-H), 3.99 (t, J = 6.8 Hz, 2H, 
5-H2), 4.85 (s, +NH, NH), 7.10 (d, J = 8.4 Hz, 1H, 4”-H), 7.29 (dd, J = 8.4 Hz, J’ = 2.0 
Hz, 1H, 3”-H), 7.38 (d, J = 2.0 Hz, 1H, 1”-H), 7.53 (dd, J = 9.2 Hz, J’ = 2.0 Hz, 1H, 7’-
H), 7.76 (d, J = 2.0 Hz, 1H, 5’-H), 8.40 (d, J = 9.2 Hz, 1H, 8’-H); 13C NMR (100.6 
MHz, CD3OD) δ 21.8 (CH2, C3’), 22.9 (CH2, C2’), 23.5 (CH2, C3), 24.8 (CH2, C1’), 
29.4 (CH2, C4’), 30.7 (CH2, C4), 36.9 (CH2, C2),  38.6 (CH2), 38.8 (CH2) (C6”, C12”), 
39.5 (CH, d, JC-F = 13.0 Hz, C5”), 40.4 (CH, d, JC-F = 13.1 Hz, C11”), 40.7 (CH2, d, JC-F 
= 19.9 Hz, C10”, C13”), 45.9 (CH2, d, JC-F = 20.6 Hz, C8”), 49.3 (CH2, C5), 58.1 (C, d, 
JC-F = 10.7 Hz, C7”), 94.0 (C, d, JC-F = 180.2 Hz, C9”), 113.5 (C, C9a’), 115.5 (C, 
C8a’), 119.1 (CH, C5’), 119.7 (CH, C3”), 121.0 (CH, C1”), 126.8 (CH, C7’), 128.8 
(CH, C8’), 129.9 (CH, C4”), 138.9 (C, C2”), 140.0 (C, C6’), 140.5 (C, C10a’), 141.0 
(C, C4a”), 145.7 (C, C11a”), 152.1 (C, C4a’), 157.9 (C, C9’), 174.0 (C, C1); HRMS 
(ESI), calcd for [C33H3835ClFN4O + H+] 561.2791, found 561.2796. 
 
4.2. Biological assays 
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4.2.1. Evaluation of hAChE and hBChE inhibitory activities 
The inhibitory activity of the target compounds towards human recombinant AChE and 
human serum BChE (Sigma, Milan, Italy) was evaluated spectrophotometrically 
following the method of Ellman et al. [61]. The enzyme stock solutions were prepared 
by dissolving human recombinant AChE or human serum BChE lyophilized powders in 
0.1% Triton X-100/0.1 M potassium phosphate, pH 8.0, or in 0.1% aq. gelatin, 
respectively. The stock solutions of the target compounds (1 mM) were prepared in 
MeOH. The assay solution consisted of 340 μM 5,5’-dithiobis(2-nitrobenzoic acid) 
(DTNB), 0.02 unit/mL hAChE or hBChE, and 550 μM acetylthiocholine iodide or 
butyrylthiocholine iodide, for AChE and BChE, respectively, in 0.1 M potassium 
phosphate, pH 8.0. Assay solutions with and without the target compounds were 
preincubated at 37 °C for 20 min, before the addition of the substrate (acetylthiocholine 
iodide or butyrylthiocholine iodide). Blank solutions containing all components except 
the enzymes were prepared in parallel to correct for non-enzymatic hydrolysis of the 
substrates. Initial rate assays were performed at 37 °C with a Jasco V-530 double beam 
spectrophotometer. At least five increasing concentrations of the target compounds, 
which led to 20–80% inhibition of the enzymatic activities, were assayed. IC50 values 
were calculated using Microcal Origin 3.5 software (Microcal Software, Inc). 
 
4.2.2. Evaluation of NMDA receptor antagonist activity 
The functional assay for the determination of the antagonistic activity of the target 
compounds at the NMDA receptors was performed using primary cultures of rat 
cerebellar granule neurons, which were prepared following established protocols [49]. 
Cells were grown on 10 mm poly-L-lysine coated glass cover slips and used for the 
experiments after 6–9 days in vitro. Cells were loaded with 6 μM Fura-2 AM 
(ThermoFisher-Invitrogen) for 30 min, and then, the coverslip was mounted on a quartz 
cuvette containing a Mg2+-free Locke-Hepes (LH) buffer using a special holder. 
Measurements were performed using a Perkin Elmer LS-55 fluorescence spectrometer 
equipped with a fast-filter accessory, under mild agitation at 37 ºC. Analysis from each 
sample was recorded real-time during 1400 s. After stimulation with NMDA (100 μM, 
in the presence of 10 μM glycine), increasing cumulative concentrations of the target 
compounds were added (range: 0.1–100 μM). To avoid precipitation, the tested 
compounds were dissolved in LH buffer containing a final concentration of 1.8% β-
cyclodextrin. The percentages of inhibition at every tested concentration were analyzed 
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using a non-linear regression curve fitting (variable slope) by using the software 
GraphPad Prism 5.0. 
 
 
4.2.3. Evaluation of BACE-1 inhibitory activity 
The inhibitory activity of the target compounds towards human recombinant BACE-1 
(β-secretase, Invitrogen) was evaluated by employing the Panvera peptide as substrate 
[71]. Ten μL of substrate (250 nM final concentration) were added to 10 μL of solution 
of the target compounds or buffer in control wells (20 mM sodium acetate, pH 4.5, 
containing CHAPS 0.1% w/v). To start the reaction 10 μL of BACE-1 enzyme were 
added (12.91 mU). The enzyme was left to react for 1 h at 37 ºC. The fluorescence 
signal was read at λem = 544 nm (λex = 590 nm) after adding 10 μL of STOP solution 
(2.5M NaOAc). The DMSO concentration in the final mixture was maintained below 
5% (v/v) to guarantee no significant loss of enzyme activity. The fluorescence 
intensities with and without inhibitor were compared and the percent of inhibition due 
to the presence of the target compounds was calculated. The background signal was 
measured in control wells containing all the reagents, except BACE-1, and was 
subtracted. The % of inhibition due to the presence of test compounds was calculated by 
the following expression: 100 – (IFi/IFo × 100), where IFi and IFo are the fluorescence 
intensities obtained for BACE-1 in the presence and in the absence of inhibitor, 
respectively. 
 
4.2.4. Evaluation of Aβ42 and tau anti-aggregating activities 
The inhibitory activities of the target compounds towards Aβ42 and tau aggregation 
were assessed using intact E. coli cells, as previously described [51,65,66]. E. coli BL21 
(DE3) competent cells were transformed with the pET28a vector (Novagen, Inc., 
Madison, WI, USA), which carryies the DNA sequence of Aβ42, or with pTARA, 
which contains the RNA-polymerase gen of T7 phage (T7RP) under the control of the 
promoter PBAD, and were then transformed with the pRKT42 vector, encoding four 
repeats of tau protein in two inserts. Ten mL of M9 minimal medium containing 50 
μg/mL of kanamycin (for Aβ42 overexpression) or 0.5% of glucose, 50 μg/mL of 
ampicillin and 12.5 μg/mL of chloramphenicol (for tau overexpression) were inoculated 
with a colony of BL21 (DE3) cells bearing the plasmids. The volume of overnight 
culture necessary to get a 1:500 dilution was added into fresh M9 minimal medium 
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containing 50 μg/mL of kanamycin and 250 µM of Th-S (for Aβ42 overexpression) or 
0.5% of glucose, 50 μg/mL of ampicillin, 12.5 μg/mL of chloramphenicol, and 250 µM 
of Th-S (for tau overexpression). The cultures were grown overnight at 37 ºC and 250 
rpm until cell density reached OD600 = 0.6. A volume of 980 L of the cultures was 
transferred into 1.5 mL eppendorf tubes that contained 10 L of a solution of the target 
compound in DMSO and 10 L of isopropyl 1-thio-β-D-galactopyranoside (IPTG) at 
100 mM (for Aβ42 overexpression) or 10 L of arabinose at 25% (for tau 
overexpression), thereby leading to a final inhibitor concentration of 10 M. The 
resulting cultures were grown overnight at 37 °C and 1400 rpm with a Thermomixer 
(Eppendorf, Hamburg, Germany). The same amount of DMSO without the target 
compound was added to the sample as a negative control (maximal amount of Aβ42 or 
tau), whereas non-induced samples (in the absence of IPTG or arabinose) were prepared 
as positive controls (absence of Aβ42 or tau), and to assess the potential intrinsic 
toxicity of the target compounds. 
The effects of the target compounds on Aβ42 or tau aggregation were assessed using a 
previously described fluorescence assay [51,65,66], by employing a 2500 mM stock 
solution of thioflavin-S (Th-S, T1892, Sigma, St. Louis, MO, USA) in double-distilled 
water (Milli-Q system, Millipore, USA), and measuring the Th-S spectra on an Aminco 
Bowman Series 2 luminescence spectrophotometer (Aminco-Bowman AB2, SLM 
Aminco, Rochester, NY, USA) in the range 460–600 nm at 25 °C, with an excitation 
wavelength of 440 nm and slit widths of 4 nm, and an emission wavelength of 485 nM. 
 
4.2.5. Evaluation of brain permeability: PAMPA-BBB assay 
The brain permeability (Pe) of the target compounds was determined by the in vitro 
parallel artificial membrane permeability assay for blood-brain barrier penetration of Di 
et al. [70], which employs a lipid extract of porcine brain membrane in PBS/EtOH 
70:30. The assay was validated by comparison of the experimental and reported Pe 
values of a set of fourteen commercial drugs (Table 2), and the following correlation 
was obtained: Pe (exp) = 1.5758 Pe (lit)  1.1459 (R2 = 0.9241). From this equation and 
the limits established by Di et al. for BBB permeation, the threshold for high BBB 
permeation (CNS+) was set at Pe (106 cm/s) > 5.16; whereas the range for low BBB 
permeation (CNS) was set at Pe (106 cm/s) < 2.01, and that for uncertain BBB 
permeation (CNS±) at 5.16 > Pe (106 cm/s) > 2.01. 
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Table 2 
Experimental and reported BBB permeability values (Pe 106 cm/s) of the 
commercial drugs used for assay validation. 
Drug Reported Pea Experimental Peb 
Cimetidine 0.0 0.7 ± 0.1 
Lomefloxacin 1.1 0.8 ± 0.1 
Norfloxazin 0.1 0.9 ± 0.1 
Ofloxazin 0.8 1.0 ± 0.1 
Hydrocortisone 1.9 1.4 ± 0.1 
Piroxicam 2.5 2.1 ± 0.1 
Clonidine 5.3 6.5 ± 0.1 
Corticosterone 5.1 6.7 ± 0.1 
Imipramine 13.0 12.3 ± 0.1 
Promazine 8.8 13.8 ± 0.3 
Progesterone 9.3 16.8 ± 0.3 
Desipramine 12.0 17.8 ± 0.1 
Testosterone 17.0 26.4 ± 0.3 
Verapamil 16.0 28.6 ± 0.3 
a Taken from [70]. b Values are expressed as the mean ± SD of three independent 
experiments. 
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